Effectiveness and Safety of Radium-223 Dichloride - Modifications in its indication

Radium-223 dichloride (Ra-223) is an alpha particle-emitting radiopharmaceutical whose licensed indication in patients with castration-resistant prostate cancer with bone metastases (CRPCm) was modified in June 2018, due to the appearance of drug-drug interactions with common drugs in CRPCm such as abiraterone and prednisone/prednisolone. Thus, it was restricted to use in monotherapy or combination with luteinizing hormone-releasing hormone analogues, becoming third-line treatment in patients with CRPCm, for which evidence on its effectiveness and safety in this new context is lacking.

About the author

Laureato in farmacia e specializzato in Radiofarmacia.

Product details

• Authors: Mª Alejandra Asensio Ruiz, Manuel Soria Soto
• Publisher: Our Knowledge Publishing
• Languages: English
• Product format: Paperback / Softback
• Released: 20.10.2023
• EAN: 9786206581642
• ISBN: 9786206581642
• No. of pages: 60
• Subject: Natural sciences, medicine, IT, technology > Medicine > Pharmacy